News

The new platform is a part of Heta-based QSP modeling infrastructure [Moscow – 11.08.2021] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, now presents HetaSimulator. It is a part of Heta project that embraces three components. HetaSimulator is an OpenSource simulation and parameters estimation platform for the Heta modeling language.

Now IRT gets significant update and a portion of new data [Moscow – 22.07.2021] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, launches Immune Response Template (IRT) version 3.5.0.

[Moscow – 19.05.2021] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, launches the new version (0.3.0) of its SbmlViewer open project. Generally, SbmlViewer is a tool for fast and easy reading and transformation of biological models written in SBML format.

InSysBio presents the major updates of Heta compiler. Heta compiler is a software tool for development of QSP modeling platforms. In fact, its core option is the compilation of Heta-based platforms. Its functionality has been significantly elaborated and now Heta compiler has become even more useful and functional.

IRT gets new data and recalculated parameters [Moscow – 30.03.2021] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, launches Immune Response Template (IRT) version 3.4.0. IRT represents a Quantitative Systems Pharmacology (QSP) platform of immune system simultaneously being a tool for development of models related to immune system. IRT is based on two main components.

[Moscow – 15.02.2021] Oleg Demin Jr, Head of Oncology and Immuno-Oncology at InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, has talked to startup.info, a global innovation ecosystem magazine. The interview in frames of the series "INNOVATORS VS COVID-19" covers the application of system-pharmacology modeling to different stages of drug research and development and InSysBio's current development in the context of the pandemic.